'Smoking cessation and pulmonary rehabilitation are the king and queen of COPD management', summarised my esteemed colleague A/Prof Jim Reid during a discussion about COPD management. Following PHARMAC's announcement to fund more medications to manage COPD, this is an important statement. While no new classes of medications are available to treat COPD, the magnitude of change in treating our patients with COPD will be similar to PHARMAC announcing that they are funding two more β-blockers, three more angiotensin antagonists, two more statins and three combinations of both. It would have hardly startled anybody -nor should the increased number of medications within the same class confuse us in managing our patients with COPD. 'Smoking, not COPD, as the disease' (click here) and 'Don't wait for COPD to treat tobacco use' (click here) are the editorials of our opinion leaders. Some of you may have followed the debate about the increase of plain tobacco packaging around the world or may have seen the Lancet announcement 'Turkmenistan bans tobacco sales'. All this may help us to stay focussed in our NZ debate to encourage smoking cessation, although the evidence whether e-cigarettes are helpful and distracting isn't quite out as yet. NZ ought to maintain its goal to become smoke-free in 2025.
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Anoro ® Ellipta ® (umeclidinium bromide 62.5mcg/vilanterol trifenatate 25mcg) and Incruse ® Ellipta ® (umeclidinium bromide 62.5mcg) are fully-funded prescription medicines for the regular treatment of COPD. Special Authority criteria apply to Anoro Ellipta. Breo ® Ellipta ® (fluticasone furoate 100mcg/vilanterol trifenatate 25mcg) is a fully-funded prescription medicine for the regular treatment of asthma (12 years of age and older) and/or COPD. Breo Ellipta 200/25mcg is a private purchase medicine indicated in asthma. Before prescribing please read the Data Sheet available from medsafe.govt.nz for contraindications, precautions and adverse events information. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. Anoro and Breo Ellipta were developed in collaboration with Theravance Inc. Summary: Qualitative in-depth interviews were used to explore the ways in which 20 Māori and Pacific smokers aged 18-26 years interpreted 'informed choice' in relation to smoking in this NZ research. An informed-choice framework was used to analyse the data with a thematic analysis approach. None of the participants met more than the framework's initial two criteria, and few regarded themselves as well informed. Most participants reflected on their unthinking uptake and subsequent addiction, and were able to identify environmental factors that facilitated uptake. Despite this context, most participants agreed they made informed choices to smoke.
Comment: NZ is being recognised for its vision to become smoke-free by 2025. Much of this impetus stems from Māori political leaders like Tau Henare and Tariana Turia, who recognised smoking was not part of Māori kaupapa and led the parliamentary 'Inquiry into the tobacco industry in Aotearoa and the consequences of tobacco use for Māori' (hyperlink). The enquiry found the smoking prevalence in Māori (38%) was more than twice that of NZ Europeans (15%). This article explores some of the cultural and socioeconomic influences that influence young Māori and Pacific adults' decision making. Bottom line: government legislation can assist smoking cessation together with contextual factors relevant to Māori and Pacific communities.
Reference: BMJ Open 2016; 6: e011415 Abstract E-cigarettes and smoking cessation in real-world and clinical settings Authors: Kalkhoran S & Glantz SA Summary: This was a systematic review and meta-analysis of 38 studies reporting on the association between e-cigarette use and cigarette smoking cessation among adults, with 20 studies with control groups (15 cohort studies, three crosssectional studies and two clinical trials) included in a random effects meta-analysis and sensitivity analyses. Compared with study participants who did not use e-cigarettes, those who did were significantly less likely to quit cigarette smoking (OR 0.72 [95% CI 0.57, 0.91]) , and the associations did not differ significantly between studies of all smokers using e-cigarettes versus those only enrolling smokers interested in stopping (ORs 0.63 vs. 0.86 [p=0.94]) . No other study characteristics had a significant impact on the overall effect size (p≥0.77).
Comment: Two RCTs, including one from NZ (Respiratory Research Review, issue 95), suggested that e-cigarettes as part of a smoking cessation programme may assist quitting. A meta-analysis on the RCT and cohort studies showed conflicting results, which led these authors to explore the role of e-cigarettes further. They included 38 studies exploring the use of e-cigarettes in the 'real word', outside smoking cessation trials; this included adults who wished to use nicotine in smoke-free areas and college students using e-cigarettes as an introductory device to cigarettes. Bottom line: outside formal smoking cessation programmes, the use of e-cigarettes was associated with a 28% lower chance of quitting.
Reference: Lancet Respir Med 2016;4(2):116-28 Abstract
For more information, please go to www.medsafe.govt.nz Health-care provider screening and advice for smoking cessation among smokers with and without COPD Authors: Schauer GL et al.
Summary:
This US study assessed the prevalence of clinician-delivered 5A strategies (ask, advise, assess, assist, arrange) in adult smokers with and without COPD; 20,021 adult past-year cigarette smokers surveyed in the 2009-2010 National Adult Tobacco Survey reported whether or not they had been a recipient of a 5A strategy in the past year. Compared with smokers without COPD, those with COPD were more likely to report being asked about tobacco use (95.4% vs. 85.8%), advised to quit (87.5% vs. 59.4%), assessed for readiness to quit (63.8% vs. 37.9%), offered assistance to quit (58.6% vs. 34.0%) and offered follow-up (14.9% vs. 5.2%).
Comment: These authors from the US report on data obtained from more than 20,000 adult smokers; the results are probably relevant to NZ. A total of 95% of smokers with COPD were asked about smoking. A total of 88% of patients with COPD were advised to quit smoking, but only 60% of patients without COPD were given the same advice. However, only 34% of patients without COPD were offered assistance to quit and only 5% were offered follow-up. Bottom line: the Ask, Brief Advice and Cessation framework is relevant to all health professionals -we need to be better at giving cessation support using the MoH and PHARMAC framework.
Reference: Chest 2016;149(3):676-84 Abstract
Independent commentary by Professor Lutz Beckert.
Professor Lutz Beckert is the Head of Department of Medicine of the University of Otago, Christchurch. He is also a Respiratory Physician at Canterbury District Health Board.
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Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please CLICK HERE. . Findings for secondary outcomes, which should be interpreted cautiously, included reduced rates of decline in FEV 1 in the combination and fluticasone furoate groups versus placebo (differences 8 mL/year for both), but not vilanterol (difference -2 mL/ year). There were no differences between the active treatments and placebo for composite CV events, but all treatments were associated with reduced rates of moderate and severe exacerbations. There were no significant differences among the groups for pneumonia or adverse cardiac events.
Comment: Does anybody remember the TORCH study, which set out to show that salmeterol/fluticasone improved survival in COPD; however, it turned out to show no effect? It must be a sense of déjà vu for the sponsor of this massive study including more than 16,000 patients in more than 1000 study centres. The data are reassuring in that the therapy does no harm, improves symptoms and reduces exacerbations. It will certainly show us many insights on COPD management in the future. Compared with placebo, 32 treatments were found to be effective for preventing moderate-to-severe exacerbations in 20 RCTs (n=26,141), with the combination of tiotropium, budesonide and formoterol being the most effective at 99.2% on the SUCRA (Surface Under the Cumulative Ranking) curve. The combination of fluticasone and salmeterol was more effective than placebo, formoterol and fluticasone alone for reducing mortality in 88 RCTs (n=97,526), and was the most effective at 71% on the SUCRA curve. For CV-related mortality, data from 37 RCTs (n=55,156) showed that: i) salmeterol was safer than placebo, tiotropium and tiotropium soft mist inhaler; ii) fluticasone was safer than tiotropium soft mist inhaler; and iii) salmeterol/fluticasone was safer than tiotropium and tiotropium soft mist inhaler; triamcinolone acetonide was the most harmful with a SUCRA value of 81%. Compared with placebo, fluticasone and fluticasone plus salmeterol were found to be associated with increased risk of pneumonia in 54 RCTs (n=61,551), with fluticasone plus salmeterol the most harmful (SUCRA value 89%). There were no significant differences among agents for arrhythmia.
Comment:
One of the features of a statistical tool of a network meta-analysis is that it allows conclusions to be drawn on the effect of treatments against placebo, even if the report was against another treatment. In this amazing analysis, Andrea Tricco and colleagues included more than 100,000 participants from more than 200 RCTs to compare safety and effectiveness of long-acting inhaled agents in the treatment of COPD. They found many trials of poor quality and at risk of bias. Bottom line: most treatments reduced the risk of exacerbations, but none improved mortality compared with placebo. . Baseline blood eosinophil count did not modify the effect on COPD exacerbation rate. Adverse events and mortality were similar between the two groups, except for a lower incidence of pneumonia with the LABA/LAMA combination than with the LABA/ICS combination (3.2% vs.
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4.8% [p=0.02]).
Comment: This European study has several surprising outcomes: i) although the authors specifically targeted patients with an exacerbation of COPD, they found the LAMA/LABA combination was superior to the LABA/ICS combination; and ii) treatment with LAMA/LABA, i.e. indacaterol/glycopyrronium, reduced the rate of exacerbations, extended the time to first exacerbation, increased the trough FEV 1 , decreased the risk of pneumonia and improved quality of life measurements. Bottom line: the FLAME study provides support for using LAMA/ LABA in GOLD groups band D. We should follow the guidelines and can stop using ICSs in patients who don't qualify for ICS use.
Reference: N Engl J Med 2016;374(23):2222-34 Abstract
Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids .76] for ≥2%, ≥4% and ≥5% of total white blood cell count), with a significant treatment-by-subgroup interaction for the 4% and 5% cutoffs only. The results were similar for eosinophil cutoffs of 300 and 400 cells/μL, and mutually exclusive subgroups.
Comment: In the FLAME study, a blood eosinophil marker of ≥2% did not identify patients who respond to a LABA/ICS regimen. Henrik Watz and colleagues present the post hoc analysis of the WISDOM trial, which demonstrated one can withdraw ICSs without an increased risk of exacerbations. The authors report that a blood eosinophil count ≥4% or 300 cells/uL may identify patients in whom it may be detrimental to withdraw ICSs. I agree with the authors rather than the editorial's bottom line: this finding needs to be confirmed in a prospective study before it can be considered in clinical practice.
Reference: Lancet Respir Med 2016;4(5):390-8 Abstract
Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease Authors: Stone IS et al.
Summary:
Forty-five patients with COPD with hyperinflated lungs received 7-14 days of fluticasone furoate 100µg plus vilanterol 25μg and placebo in a randomised crossover design with a ≥7-day washout. Compared with placebo, the ICS/LABA combination was associated with a significant increase in change from baseline RV end-diastolic volume index (primary outcome) of 5.8 mL/m 2 , a significant reduction in residual volume of 429mL, and significant increases in LV end-diastolic and left atrial end-systolic volumes of 3.63 and 2.33 mL/m 2 (p=0.002). A post hoc analysis showed that RV stroke volume increased by 4.87 mL/m 2 (p=0.003), while RV ejection fraction did not change. LV adaptation was similar; left atrial ejection fraction increased significantly by 3.17%. There was no change in intrinsic myocardial function. Pulmonary main and left artery pulsatility increased significantly by 2.9% and 2.67%, respectively. Safety of the ICS/LABA combination was similar to placebo.
Comment: This is a rather complex proof-of-concept study to which Henrik Watz wrote a most learned editorial, which I recommend reading. The partially GSK-based team use cardiac MRI scans in patients with hyperinflation to demonstrate an increase in the RV end-diastolic volume of about 7.5% (6 mL/m 2 ) after treatment with vilanterol/fluticasone furoate. This corresponded with a reduction in hyperinflation and an increase in RV stroke volume. Bottom line: bronchodilator therapy deflated the lung and counteracted treatable underfilling of the heart in COPD patients with hyperinflated lungs.
Reference: Am J Respir Crit Care Med 2016; 193(7) :717-26 Abstract A product your patients can count on. For more information, please go to www.medsafe.govt.nz Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. Research Review publications are intended for New Zealand health professionals.
CONGRATULATIONS TO
Anne Brinkman
Professional Nursing Advisor at NZNO. Summary: This study investigated whether β-blockers reduced the frequency of acute exacerbations in 3464 patients with GOLD stage 2-4 COPD who were participating in a prospective follow-up of the COPDGene cohort. Total and severe exacerbation rates were compared between groups categorised according to β-blocker use. β-blocker use was associated with significantly lower rates of total and severe exacerbations during follow-up of median 2.1 years (respective incidence risk ratios 0.73 [95% CI 0.60, 0.90] and 0.67 [0.48, 0.93] ), and these rates were also lower among participants with GOLD stage 3-4 disease and on home oxygen (0.33 [0.19, 0.58] and 0.35 [0.16, 0.76]) , with the greatest reduction seen for GOLD stage B. β-blocker use had no effect on all-cause mortality.
Comment: It is probably one of our most hotly debated paradoxes in respiratory medicine, that therapy with LABA/LAMAs improves symptoms but not survival in patients with COPD, while therapy with β-blockers may reduce exacerbations and possibly improves survival. Here the authors of the American based COPDGene study prospectively followed almost 3500 patients with COPD for about 2 years. The use of β-blockers was associated with a significantly lower rate of severe exacerbations, particularly in the GOLD B group. Bottom line: while we are awaiting prospective studies, you may enjoy the remarkable summary of our local colleagues on 'cardiac dysfunction during exacerbation of COPD'.
